Actimis Pharmaceuticals, Inc., is a start-up biopharmaceutical company focused on the development of small molecule therapeutics for respiratory and inflammatory disorders. Actimis was created as a spin-off from the respiratory diseases therapeutic research portfolio of Bayer Healthcare AG. The spin-off was founded by Dr. Kevin Bacon and has received venture financing from a syndicate lead by Sanderling Ventures of San Mateo, California and Mitsui & Co Venture Partners of New York. Dr. Bacon was most recently Vice President and Global Head of Respiratory diseases research at Bayer Yakuhin Ltd., Japan where the programs were initiated.